Provided by Tiger Trade Technology Pte. Ltd.

Eton Pharmaceuticals, Inc.

63.47
+3.565.94%
Post-market: 63.940.4700+0.74%19:44 EDT
Volume:640.79K
Turnover:40.08M
Market Cap:1.81B
PE:162.74
High:64.00
Open:59.76
Low:59.76
Close:59.91
52wk High:64.00
52wk Low:14.27
Shares:28.58M
Float Shares:26.68M
Volume Ratio:0.56
T/O Rate:2.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3900
EPS(LYR):-0.1710
ROE:35.97%
ROA:11.86%
PB:38.94
PE(LYR):-371.19

Loading ...

U.S. Earnings Preview: After Market Close Aug. 13

Dow Jones
·
Aug 14

Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), Eton Pharmaceuticals (ETON) and Dyadic International (DYAI)

TIPRANKS
·
Aug 13

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 13

What Could Eton Pharmaceuticals (ETON) Gain From The ASN 001 Licensing Deal?

Simply Wall St.
·
Aug 13

Eton Pharma COO Danka Radosavljevic Files Initial Beneficial Ownership Statement

Reuters
·
Aug 13

Eton Pharmaceuticals Inc Expected to Post Earnings of 11 Cents a Share - Earnings Preview

Reuters
·
Aug 12

Eton Pharmaceuticals Inc : H.c. Wainwright Raises Target Price to $65 from $57

THOMSON REUTERS
·
Aug 11

Earning Preview: Eton Pharmaceuticals, Inc. Q2 revenue is expected to increase by 62.24%, and institutional views are bullish

Earnings Agent
·
Aug 06

Eton Pharmaceuticals Plans ASN-001 NDA Submission in 2H 2027 After Infantile Hemangioma Phase Ii/iii Data

Reuters
·
Aug 05

Eton Pharmaceuticals Licenses US Rights to Auson’s ASN-001 for Infantile Hemangiomas

Reuters
·
Aug 05

Eton Pharmaceuticals - Anticipates Nda Submission for Asn-001 in 2H 2027, Potential Launch in 2028

THOMSON REUTERS
·
Aug 05

Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate Asn-001

THOMSON REUTERS
·
Aug 05

Eton Pharmaceuticals Names Danka Radosavljevic Chief Operating Officer

Reuters
·
Aug 04

Eton Pharma to Report Q2 2026 Results, Host Conference Call and Webcast

Reuters
·
Aug 03

Is Eton Pharmaceuticals (ETON) Quietly Reframing Its Orphan-Drug Strategy With KHINDIVI’s Label Expansion Bid?

Simply Wall St.
·
Jul 30

Eton Pharma Submits FDA Supplement to Expand Khindivi Label to Younger Pediatric Patients

Reuters
·
Jul 29

Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of Khindivi® (Hydrocortisone) Oral Solution

THOMSON REUTERS
·
Jul 29

Eton Pharmaceuticals is Maintained at Buy by Craig-Hallum

Dow Jones
·
Jul 29

Eton Pharmaceuticals price target raised to $62 from $40 at Craig-Hallum

TIPRANKS
·
Jul 28

Eton Pharmaceuticals (ETON) Stock Looks Overvalued Even After Recent Wins

Simply Wall St.
·
Jul 18